

Table 7.6i
Immunosuppression Use for Antirejection Treatment from Transplant
to One Year Following Transplantation, 1997 to 2006
Recipients with Pancreas After Kidney (PAK) Transplants

	Year of Transplant									
	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
Transplants	130	156	220	304	305	375	344	420	343	293
Tx with Antirejection Treatments	41	44	57	65	45	43	61	59	46	31
Antibodies										
Any in Category	61.0%	59.1%	75.4%	53.8%	60.0%	48.8%	65.6%	59.3%	76.1%	67.7%
Atgam/NRATG/NRATS	17.1%	9.1%	1.8%	1.5%	2.2%	0.0%	3.3%	0.0%	0.0%	0.0%
OKT3	51.2%	45.5%	63.2%	35.4%	26.7%	25.6%	13.1%	15.3%	13.0%	16.1%
Thymoglobulin	0.0%	2.3%	22.8%	21.5%	33.3%	30.2%	45.9%	44.1%	63.0%	58.1%
Zenapax	0.0%	2.3%	1.8%	1.5%	2.2%	2.3%	6.6%	0.0%	4.3%	3.2%
Simulect	0.0%	0.0%	0.0%	4.6%	4.4%	0.0%	4.9%	0.0%	2.2%	3.2%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	27.9%	8.5%	6.5%	3.2%
Corticosteroids										
Any in Category	78.0%	70.5%	84.2%	87.7%	86.7%	90.7%	68.9%	79.7%	63.0%	71.0%
Steroids	78.0%	70.5%	84.2%	87.7%	86.7%	90.7%	68.9%	79.7%	63.0%	71.0%
Antimetabolites										
Any in Category	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Methotrexate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 1, 2008.

Notes:

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.